A tetracycline-regulated adenoviral expression system for in vivo delivery of transgenes to lung and liver

Journal of Gene Medicine

Volumn 5, Issue 7, 2003, Pages 567-575

  Tietge, Uwe J F ^a   Kozarsky, Karen F ^a,b   Donahee, Mary H ^a,b   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Adenovirus; Gene transfer; Secretory phospholipase A2; Tetracycline

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; COMPLEMENTARY DNA; PHOSPHOLIPASE A2; SECRETORY PROTEIN; TETRACYCLINE; TRANSACTIVATOR PROTEIN; GROUP II SECRETORY PHOSPHOLIPASE A2; HYBRID PROTEIN; PHOSPHOLIPASE A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; GENE CONSTRUCT; GENE EXPRESSION REGULATION; GENE EXPRESSION SYSTEM; GENE THERAPY; GENE TRANSFER; GENETIC CODE; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER; LUNG; MARKER GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET ORGAN; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; WESTERN BLOTTING; ADENOVIRUS; ANIMAL; C57BL MOUSE; CELL CULTURE; EVALUATION; GENE TARGETING; GENE VECTOR; GENETICS; LACTOSE OPERON; METABOLISM; PHYSIOLOGY;

ADENOVIRIDAE; ANIMALS; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HELA CELLS; HUMANS; LAC OPERON; LIVER; LUNG; MICE; MICE, INBRED C57BL; PHOSPHOLIPASES A; RECOMBINANT FUSION PROTEINS; TETRACYCLINE; TRANS-ACTIVATORS; TRANSGENES;

EID: 2142734866     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.384     Document Type: Article

References (50)

1. Wilson JM. Adenoviruses as gene delivery vehicles. N Engl J Med 1996; 334: 1185-1187.
2. Ali M, Lemoine NR, Ring CJA. The use of DNA viruses as vectors for gene therapy. Gene Ther 1994; 1: 367-384.
3. Shenk T. Adenoviridae: the viruses and their replication. In Virology, Fields BN, Knipe DM, Howley PM (eds). Raven: New York, 1996; 2111-2148.
4. Kozarsky KF, Wilson JM. Gene therapy: adenovirus vectors. Curr Opin Gene Dev 1993; 3: 499-503.
5. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 1992; 89: 5547-5551.
6. Shockett PE, Schatz DG. Diverse strategies for tetracycline-regulated inducible gene expression. Proc Natl Acad Sci U S A 1996; 93: 5173-5176.
7. Kistner A, Gossen M, Zimmermann F, et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A 1996; 93 10 933-10 938.
8. Furth PA, Onge LS, Böger H, et al. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci U S A 1994; 91: 9302-9306.
9. Mayford M, Bach ME, Huang Y, et al. Control of memory formation through regulated expression of a CaMKII transgene. Science 1996; 274: 1678-1683.
10. Massie B, Couture F, Lamoureux L, et al. Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette. J Virol 1998; 72 2289-2296.
11. Rubinchik S, Ding R, Qiu AJ, et al. Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system. Gene Ther 2000; 7: 875-885.
12. Yoshida Y, Emi N, Hamada H. VSV-G-Pseudotyped retroviral packaging through adenovirus-mediated inducible gene expression. Biochem Biophys Res Commun 1997; 232: 379-382.
13. Hu S-X, Ji W, Zhou Y, et al. Development of an adenovirus vector with tetracyclin-regulatable human tumor necrosis factor a gene expression. Cancer Res 1997; 57: 3339-3343.
14. Kojima H, Abiru Y, Sakajiri K, et al. Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain. Biochem Biophys Res Commun 1997; 238 569-573.
15. Harding TC, Geddes BJ, Murphy D, et al. Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system. Nat Biotechnol 1998; 16: 553-555.
16. Molin M, Shoshan MC, Öhman-Forslund K, et al. Two novel adenovirus vector systems permitting regulated protein expression in gene transfer experiments. J Virol 1998; 72: 8358-8361.
17. Mano T, Luo Z, Suhara T, et al. Expression of wild-type and noncleavable Fas ligand by tetracycline-regulated adenoviral vectors to limit intimal hyperplasia in vascular lesions. Hum Gene Ther 2000; 11: 1625-1635.
18. Nakagawa S, Massie B, Hawley RG. Tetracycline-regulatable adenovirus vectors: pharmacologic properties and clinical potential. Eur J Pharm Sci 2001; 13: 53-60.
19. Tietge UJF, Maugeais C, Cain W, et al. Overexpression of secretory phospholipase A2 causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J Biol Chem 2000; 275: 10 077-10 084.
20. Mournier CM, Hackeng TM, Schaeffer F, et al. Inhibition of prothrombinase by human secretory phospholipase A2 involves binding to factor Xa. J Biol Chem 1998; 273: 23 764-23 772.
21. Laine VJO, Grass DS, Nevalainen TJ. Protection by group II phospholipase A2 against staphylococcus aureus. J Immunol 1999; 162: 7402-7408.
22. Hack CE, Wolbink G-J, Schalkwijk C, et al. A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells. Immunol Today 1997; 18: 111-115.
23. Cormier RT, Hong KH, Halberg RB, et al. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat Genet 1997; 17: 88-91.
24. MacPhee M, Chepenik KP, Liddell RA, et al. The secretory phospholipase A2 gene is a candidate for the Moral locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 1995; 81: 957-966.
25. Shiratori Y, Kanai F, Ohashi M, et al. Strategy of liver-directed gene therapy: present status and future prospects. Liver 1999; 19: 265-274.
26. Jaffe A, Bush A, Geddes DM, et al. Prospects for gene therapy in cystic fibrosis. Arch Dis Child 1999; 80: 286-289.
27. Tangirala RK, Tsukamoto K, Chun SH, et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999; 100: 1816-1822.
28. Tsukamoto K, Tangirala R, Chun SH, et al. Rapid regression of atherosclerosis induced by liver-directed gene transfer of apoE in apoE-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19: 2162-2170.
29. Tietge UJF, Bakillah A, Maugeais C, et al. Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased in vivo secretion of VLDL triglycerides and apolipoprotein B. J Lipid Res 1999; 40: 2134-2139.
30. Paulus W, Baur I, Boyce FM, et al. Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J Virol 1996; 70: 62-67.
31. Barr E, Carroll J, Kalynych AM, et al. Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Ther 1994; 1: 51-58.
32. Ye X, Robinson M, Batshaw M, et al. Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors. J Biol Chem 1996; 271: 3639-3646.
33. Kozarsky KF, Jooss K, Donahee M, et al. Effective treatment of familial hypercholesterolemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nature Genet 1996; 13: 54-62.
34. Tsukamoto K, Smith P, Glick JM, et al. Liver-directed gene transfer and prolonged expression of three major human apoE isoforms in apoE-deficient mice. J Clin Invest 1997; 100: 107-114.
35. Kozarsky KF, Donahee MH, Rigotti A, et al. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 1997; 387: 414-417.
36. Yoshida Y, Hamada H. Adenovirus-mediated inducible gene expression through tetracycline-controllable transactivator with nuclear localization signal. Biochem Biophys Res Commun 1997; 230: 426-430.
37. Kozarsky KF, Mckinley DR, Austin LL, et al. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenovirus. J Biol Chem 1994; 269: 13 695-13 702.
38. Reynolds LJ, Hughes LL, Dennis EA. Analysis of human synovial fluid phospholipase A2 on short chain phosphatidylcholine-mixed micelles: development of a spectrophotometric assay suitable for a microtiter reader. Anal Biochem 1992; 204: 190-197.
39. Balsinde J, Balboa MA, Dennis EA. Functional coupling between secretory phospholipase A2 and cyclooxygenase-2 and its regulation by cytosolic group iV phospholipase A2. Proc Natl Acad Sci U S A 1998; 95: 7951-7956.
40. Murakami M, Kambe T, Shimbara S, et al. Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. J Biol Chem 1999; 274: 3103-3115.
41. Kojima H, Ohishi N, Yagi K. Generation of recombinant adenovirus vector with infectious adenoviral genome released from cosmid-based vector by simple procedure allowing complex manipulation. Biochem Biophys Res Commun 1998; 246: 868-872.
42. He T-C, Zhou S, Costa LTD, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998; 95: 2509-2514.
43. Yin DX, Zhu L, Schimke RT. Tetracycline controlled gene expression system achieves high-level and quantitative control of gene expression. Anal Biochem 1996; 235: 195-201.
44. Stocco DM. An update on the mechanism of action of the steroidogenic acute regulatory (StAR) protein. Exp Clin Endocrinol Diabetes 1999; 107: 229-235.
45. Kallen CB, Arakane F, Christenson LK, et al. Unveiling the mechanism of action and regulation of the steroidogenic acute regulatory protein. Mol Cell Endocrinol 1998; 145: 39-45.
46. Ghersa P, Gobert RP, Sattonnet-Roche P, et al. Highly controlled gene expression using combinations of a tissue-specific promoter, recombinant adenovirus and a tetracycline-regulatable transcription factor. Gene Ther 1998; 5: 1213-1220.
47. Dejneka NS, Auricchio A, Maguire AM, et al. Pharmacologically regulated gene expression in the retina following transduction with viral vectors. Gene Ther 2001; 8: 442-446.
48. Paillard F. Promoter attenuation in gene therapy: causes and remedies. Hum Gene Ther 1995; 6: 2009-2010.
49. Qin L, Ding Y, Pahud DR, et al. Promoter attenuation in gene therapy: interferon-y and tumor necrosis factor-α inhibit transgene expression. Hum Gene Ther 1997; 8: 2019-2029.
50. Yu M, Jerome RE, Edenberg HJ. A negative regulatory element upstream from the mouse Adh-1 gene can down-regulate a heterologous promoter. Gene 1994; 141: 249-254.